July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
1 citations
,
January 2010 in “Endocrine abstracts”
11 citations
,
February 2020 in “Dermatology and therapy” Low-Level Light Therapy significantly reduced inflammation and promoted hair regrowth in patients with Lichen planopilaris.
16 citations
,
January 2020 in “Annals of the rheumatic diseases” Baricitinib might help treat hair loss in lupus patients, but more research is needed.
January 2021 in “Journal of Cutaneous and Aesthetic Surgery” Follicular unit extraction successfully restored hair growth in a leprosy patient without disease relapse.
29 citations
,
March 2016 in “Dermatologic therapy” Platelet-rich plasma may successfully treat lichen planopillaris, as shown by one patient's symptom regression.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
13 citations
,
February 2013 in “BMJ Case Reports” Stopping finasteride improved seizure control, suggesting neurosteroids affect seizures and treatment.
33 citations
,
March 2017 in “Dermatologic Surgery” Low-level laser therapy effectively treats female hair loss, increasing hair count by 51%.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
January 2021 in “Acta Scientiae Veterinariae” Levothyroxine effectively treated a dog's skin and hair problems caused by hypothyroidism.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
May 2015 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil may improve symptoms and stop hair loss in Lichen planopilaris, but more research is needed.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
13 citations
,
February 2025 in “ChemMedChem” Lipid nanoparticles improve treatment delivery and are key to future therapies, but challenges in manufacturing and safety remain.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
2 citations
,
February 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Impaired LEF1 activation speeds up skin cell development in Hutchinson-Gilford Progeria Syndrome.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
17 citations
,
February 2019 in “Journal of Clinical Medicine” Testosterone replacement therapy should be used for men with low testosterone levels and symptoms of hypogonadism, after careful diagnosis and considering individual needs.
January 2025 in “ARC Journal of Clinical Case Reports” Encapsulated retinol may effectively treat actinic keratosis without side effects.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
3 citations
,
October 2024 in “Advances in Therapy” Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
December 2011 in “Thorax” People from iodine-deficient areas are more likely to develop hypothyroidism when treated for multi-drug resistant tuberculosis.
Injecting patients' own PRP into their thyroid improved thyroid function and symptoms in most hypothyroidism cases.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
January 2016 in “프로그램북(구 초록집)” The thulium laser and PDRN injections effectively improved hair thickness in patients with pattern hair loss.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.